Fig 4. In vivo killing assay.
C57BL/6 mice were vaccinated intradermally with 10 μg of the solution or powder formulation of GTL001 on day 0. Immediately and 24 h after vaccination, 25 mg of 5% imiquimod cream/ear was applied at each vaccination site. On day 6, the mice were injected via the retro-orbital venous sinus with CFSE-labeled splenocytes from naïve C57BL/6 mice that had been pulsed with MHC class I/H-2b restricted peptides of HPV16 and HPV18 E7 (HPV16 E749-57 and HPV18 E7AS43-49) or no addition. Splenocytes were collected the next day (day 7) and analyzed by flow cytometry to measure antigen-specific CD8+ T cell-mediated killing. Each dot represents the percent CD8-mediated in vivo killing for an individual mouse. Horizontal bars indicate means for each group of mice. Data were pooled from 3 independent experiments. P-values were determined by Newman-Keuls test.